<div id="readability-page-1"><div>Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings.Hair loss biotech Veradermics (MANE), priced its upsized IPO above the range to raise $256 million at a $612 million market cap. The dermatologist-founded, late clinical-stage biopharmaceutical company is developing an oral, non-hormonal extended-release formulation of minoxidil for male and female pattern hair loss. Veradermics has fully enrolled its Phase 2/3 trial in men and has initiated two additional Phase 3 registration-directed trials in male and female patients to support an NDA, targeting a large, underserved population. Veradermics finished the week up 126%.Electrical equipment maker Forgent Power Solutions (FPS) priced its IPO at the midpoint to raise $1.5 billion at an $8.2 billion market cap. At pricing, Forgent is coming public at 24x 2026 EBITDA, two turns above the median of a peer group of primarily larger, more well-established electrical distribution equipment providers. The designer and manufacturer of electrical distribution equipment serves data centers, power grids, and industrial facilities with a broad suite of products, including transformers and switchgear. Forgent finished the week up 25%.Furniture retailer Bob’s Discount Furniture (BOBS) priced its IPO at the low end of the range to raise $331 million at a $2.3 billion market cap. Bob's is coming to market at roughly 8x 2027 EBITDA, a discount to the multiples of Arhaus (11x) and RH (10x) as well as a broader group of furniture and home goods retailers. Bob’s finished the week down 3%.Jennifer Garner’s baby food brand Once Upon a Farm (OFRM) priced its IPO at the midpoint to raise $198 million at an $811 million market cap. While the company offers well-above average growth, it is amongst the smallest of its peers and remains unprofitable, unlike nearly all of its peers, though its margins are improving rapidly. Once Upon a Farm finished out the week up 17%.Chronic eye condition biotech SpyGlass Pharma (SGP) priced its IPO at the midpoint to raise $150 million at a $549 million market cap. SpyGlass is a late-stage biopharmaceutical company focused on chronic eye conditions by developing durable drug delivery solutions that provide long-term disease control and vision preservation. It finished the week up 65%.Belgian fibrotic disease biotech AgomAb Therapeutics (AGMB) priced its US IPO at the midpoint to raise $200 million at an $875 million market cap. AgomAb is advancing novel organ-restricted ALK5 inhibitors, targeting a well-established pathway for fibrosis while avoiding systemic toxicities. Both Crohn’s disease and IPF therapies are multi-billion-dollar markets, despite the limited efficacy of existing drugs, underscoring the blockbuster potential of AgomAb’s pipeline. AgomAb finished the week down 8%.Eikon Therapeutics (EIKN) priced its upsized IPO at the top of the range to raise $381 million at a $1.0 billion market cap. Led by former Merck execs, Eikon raised over $1.1 billion as a private company, most recently raising $351 million in February 2025 at an as-converted price of $43.55 per share. According to media reports, Merck intended to invest $30 million on the IPO. It is important to note that the biotech has a high cash burn rate, and its original discovery platform, built around super-resolution microscopy, is relatively unproven. Eikon's appeal to investors primarily rests on CEO Roger Perlmutter and his team's earlier successes at Merck. Eikon finished the week down 20%.Six SPACs also priced this week. Hennessy Capital VIII (HCICU) raised $210 million in an upsized IPO to target industrial innovation and energy. Cantor Equity Partners VI (CEPS), the fifteenth blank check company formed by Cantor Fitzgerald, raised $100 million. Colombier Acquisition III (CLBR.U), led by Omeed Malik and 1789 Capital Executives, raised $260 million. SPACSphere Acquisition (SSACU), led by veterans Bala Padmakumar and Soumen Das, raised $150 million. Iris Acquisition II (IRABU), led by executives from Arrow Capital, raised $150 million. Cambridge Acquisition (CAQUU) raised $200 million to target the tech sector.</div>Five SPACs also submitted initial filings. MOZAYYX Acquisition (MZYX.U) filed to raise $250 million, targeting tech, fintech, and high growth areas. Kensington Capital VI (KCAC.U) filed to raise $200 million, targeting the auto industry. Metals Acquisition II (MTAL.U) also filed to raise $200 million, targeting mining. Pono Capital Four (PONOU) filed to raise $150 million, targeting disruptive technology. Apeiron Acquisition I (APNU) filed to raise $70 million, targeting international operations.</div>

MANE

Seven IPOs and six SPACs were priced this week, marking one of the busiest weeks in four years. Notable IPOs include Veradermics, which raised $256 million, and Forgent Power Solutions, which raised $1.5 billion. Other companies like Bob’s Discount Furniture and Once Upon a Farm also made their market debuts. SPACs raised a total of $1.1 billion, with several others filing for future offerings. This surge in IPO activity reflects a growing interest in the market, particularly in biotech and technology sectors.

- This week, the IPO market saw seven IPOs and six SPACs priced, along with five IPO filings and five SPAC filings.  
- Notable IPOs included Veradermics, raising $256 million for an innovative hair loss treatment, and Forgent Power Solutions, which raised $1.5 billion for electrical distribution equipment.  
- Several SPACs also raised significant capital, including Hennessy Capital VIII with $210 million aimed at industrial innovation and energy.

US IPO Weekly Recap: Seven IPOs make it one of the busiest weeks in four years